Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05961592 · ClinicalTrials.gov registry record · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
A Phase 1 study of Arthritis, Rheumatoid, sponsored by Rise Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
- 5
- Study locations
NCT05961592: Recruiting Phase 1 study of Arthritis, Rheumatoid, sponsored by Rise Therapeutics.
NCT05961592 is a Phase 1 study of Arthritis, Rheumatoid that is actively recruiting participants, run by Rise Therapeutics. The registered enrollment target is 73 participants, below the 638-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05961592, a Phase 1 study of Arthritis, Rheumatoid, is actively recruiting participants, sponsored by Rise Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Rheumatoid Arthritis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.
Primary Outcome
To assess the number of participants with treatment-related adverse events after taking R-2487 (probiotic)
Conditions Studied
Interventions
- DRUG R-2487 DP
Study Locations (5)
Florida
- St.Jude Clinical Research - Doral
- AP Medical Research - Miami
California
- University of California, San Diego - San Diego
Pennsylvania
- Altoona Center for Research - Duncansville
Texas
- Prolato Clinical Research Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2023-10-19 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT05961592 shows while recruiting
NCT05961592 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 638-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 1 intervention - of which R-2487 DP is the first listed.
NCT05961592 lists 5 locations in 4 states (Florida, California, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT05961592 about?
NCT05961592 is a clinical study titled "R-2487 in Patients With Rheumatoid Arthritis". The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Rheumatoid Arthritis. Blood and fecal evaluations of infl...
What is the current status of trial NCT05961592?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2023-10-19. Estimated completion is 2026-12-31.
What conditions does trial NCT05961592 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
What interventions are being tested in trial NCT05961592?
The interventions under investigation include: R-2487 DP (DRUG).
Who is sponsoring clinical trial NCT05961592?
This trial is sponsored by Rise Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05961592 being conducted?
This trial has 5 study locations across California, Florida, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05961592's enrollment target sits among peer trials
73 23rd of 27 higher than 5 of 27 other Arthritis, Rheumatoid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis, Rheumatoid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection
COMPLETED · Phase 1
-
Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis
COMPLETED · Phase 1
-
A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis
COMPLETED · Phase 1
-
Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA
COMPLETED · Phase 1
-
Chronic Pain in Rheumatoid Arthritis
RECRUITING
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- NCT06247345 · 73 participants · Phase 1
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI